IL319010A - NGF for the treatment of spasticity - Google Patents
NGF for the treatment of spasticityInfo
- Publication number
- IL319010A IL319010A IL319010A IL31901025A IL319010A IL 319010 A IL319010 A IL 319010A IL 319010 A IL319010 A IL 319010A IL 31901025 A IL31901025 A IL 31901025A IL 319010 A IL319010 A IL 319010A
- Authority
- IL
- Israel
- Prior art keywords
- spasticity
- ngf
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22197562.6A EP4342485A1 (en) | 2022-09-23 | 2022-09-23 | Ngf for the treatment of spasticity |
| PCT/EP2023/076387 WO2024062135A1 (en) | 2022-09-23 | 2023-09-25 | Ngf for the treatment of spasticity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319010A true IL319010A (en) | 2025-04-01 |
Family
ID=83438536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319010A IL319010A (en) | 2022-09-23 | 2023-09-25 | NGF for the treatment of spasticity |
Country Status (10)
| Country | Link |
|---|---|
| EP (3) | EP4342485A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025532676A (cg-RX-API-DMAC10.html) |
| CN (1) | CN120239610A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023345675A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3266315A1 (cg-RX-API-DMAC10.html) |
| DK (1) | DK4590324T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI4590324T3 (cg-RX-API-DMAC10.html) |
| IL (1) | IL319010A (cg-RX-API-DMAC10.html) |
| PT (1) | PT4590324T (cg-RX-API-DMAC10.html) |
| WO (1) | WO2024062135A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4623927A1 (en) | 2024-03-27 | 2025-10-01 | Dompe' Farmaceutici SpA | Ngf for use in the prevention or treatment of motor impairment caused by neonatal hypoxic-ischemic encephalopathy |
| WO2026022244A1 (en) | 2024-07-23 | 2026-01-29 | Chiesi Farmaceutici S.P.A. | A polypeptide for use in the therapeutic management of acute ischaemic stroke |
| US20260166124A1 (en) * | 2024-12-17 | 2026-06-18 | Dompe` farmaceutici S.P.A. | Intranasal administration of ngf for the prevention or treatment of retinopathies and optic nerve disorders |
| EP4763217A1 (en) * | 2024-12-17 | 2026-06-24 | Dompé farmaceutici SpA | Intranasal administration of ngf for the prevention or treatment of retinopathies and optic nerve disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257514T1 (de) | 1998-10-09 | 2004-01-15 | Scil Proteins Gmbh | Verfahren zur gewinnung von aktivem beta-ngf |
| CN1112215C (zh) * | 1999-12-28 | 2003-06-25 | 潘晓东 | 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 |
| ES2545701T3 (es) | 2011-12-19 | 2015-09-15 | Wacker Chemie Ag | Nuevos mutantes de proNGF y usos de los mismos en la producción de beta-NGF |
| CN109071678B (zh) * | 2016-03-18 | 2022-05-20 | 舒泰神（北京）生物制药股份有限公司 | 神经生长因子融合蛋白、制备方法及其用途 |
| IT201600112420A1 (it) * | 2016-11-08 | 2018-05-08 | Univ Cattolica Del Sacro Cuore | Nuova formulazione per via intranasale |
| WO2019207106A1 (en) | 2018-04-27 | 2019-10-31 | Chiesi Farmaceutici Spa | Production of nerve growth factor (ngf) and of muteins thereof |
| AU2020347812B2 (en) * | 2019-09-17 | 2026-05-28 | Chiesi Farmaceutici S.P.A. | Agent for use in treatment or prevention of ophthalmic disorders |
| WO2022105847A1 (en) * | 2020-11-19 | 2022-05-27 | Staidson (Beijing) Biopharmaceuticals Co. , Ltd. | Long-acting nerve growth factor polypeptides and uses thereof |
-
2022
- 2022-09-23 EP EP22197562.6A patent/EP4342485A1/en not_active Withdrawn
-
2023
- 2023-09-25 FI FIEP23777211.6T patent/FI4590324T3/fi active
- 2023-09-25 DK DK23777211.6T patent/DK4590324T3/da active
- 2023-09-25 PT PT237772116T patent/PT4590324T/pt unknown
- 2023-09-25 EP EP23777211.6A patent/EP4590324B1/en active Active
- 2023-09-25 IL IL319010A patent/IL319010A/en unknown
- 2023-09-25 WO PCT/EP2023/076387 patent/WO2024062135A1/en not_active Ceased
- 2023-09-25 AU AU2023345675A patent/AU2023345675A1/en active Pending
- 2023-09-25 CN CN202380067388.4A patent/CN120239610A/zh active Pending
- 2023-09-25 CA CA3266315A patent/CA3266315A1/en active Pending
- 2023-09-25 JP JP2025517344A patent/JP2025532676A/ja active Pending
- 2023-09-25 EP EP26179026.5A patent/EP4772196A3/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4772196A3 (en) | 2026-08-19 |
| DK4590324T3 (en) | 2026-07-20 |
| CA3266315A1 (en) | 2024-03-28 |
| JP2025532676A (ja) | 2025-10-01 |
| EP4342485A1 (en) | 2024-03-27 |
| EP4590324B1 (en) | 2026-06-24 |
| EP4590324A1 (en) | 2025-07-30 |
| WO2024062135A1 (en) | 2024-03-28 |
| FI4590324T3 (fi) | 2026-07-29 |
| PT4590324T (pt) | 2026-07-20 |
| CN120239610A (zh) | 2025-07-01 |
| EP4772196A2 (en) | 2026-07-08 |
| AU2023345675A1 (en) | 2025-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3266315A1 (en) | Nerve Growth Factor (NGF) for the Treatment of Spasticity | |
| ZA202210745B (en) | Method for the production of aav | |
| GB202020573D0 (en) | Novel methods of therapy | |
| GB202003618D0 (en) | Gene Therapy | |
| CA221425S (en) | Therapy eye-mask | |
| SI3864053T1 (sl) | Zdravljenje rms-ja z menjavo terapije | |
| GB202020572D0 (en) | Novel methods of therapy | |
| ZA202400747B (en) | Environmental-friendly process for the treatment of wastewater | |
| IL306119A (en) | Gene therapy for the treatment of beta-hemoglobinopathies | |
| GB201907305D0 (en) | Treatment of conditions | |
| GB201905810D0 (en) | Method of treatment | |
| HUE067878T2 (hu) | Eljárás alkilamidotiazolok gyártásához | |
| GB202214445D0 (en) | Gene therapy | |
| GB202003867D0 (en) | Treatment of limbl spasticity | |
| GB202206346D0 (en) | Gene therapy | |
| GB202011523D0 (en) | Neuromodulation for the treatment of critical illness | |
| GB202206348D0 (en) | Treatment of limb spasticity | |
| GB202003803D0 (en) | Treatment of limb spasticity | |
| GB202315877D0 (en) | Therapy | |
| GB202306826D0 (en) | Therapy | |
| GB202306833D0 (en) | Therapy | |
| GB202306835D0 (en) | Therapy | |
| GB202303026D0 (en) | Therapy | |
| GB202219335D0 (en) | Therapy | |
| GB202315695D0 (en) | TReatment of cariomyopathy |